CERS News and Press, Cerus Corporation From 02/20/20

Cerus Corporation (Nasdaq: CERS) today announced complete financial results for the fourth quarter and year ended December 31, 2019. Recent developments and highlights include: Total fourth quarter revenue of $26.5 million. Record fourth quarter product revenue of $20.9 million,...

Collaboration with the National Trauma Institute Cerus Corporation (Nasdaq: CERS) today announced a collaboration with the National Trauma Institute (NTI) to supply INTERCEPT plasma for use in the Plasma Resuscitation Without Lung Injury (PROpOLIs) clinical study. PROpOLIs is sponsored...

Cerus Corporation (Nasdaq:CERS) announced today that its fourth quarter and full year 2019 financial results will be released on Thursday, February 20, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which m...

Cerus Corporation (Nasdaq: CERS) announced today the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares. Total proceeds for t...

Cerus Corporation (Nasdaq: CERS) announced today the pricing of a registered underwritten public offering of its common stock for proceeds of approximately $55.0 million, before deducting estimated offering expenses payable by Cerus. The offering is expected to close January 31, 2020, subject...

Cerus Corporation (Nasdaq: CERS) announced today that it has commenced a registered underwritten public offering of $50.0 million of its common stock. In addition, Cerus expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock. All of t...

Emergence of the 2019 novel coronavirus (2019-nCoV) underscores the benefits of a proactive approach to enhancing the safety and availability of the blood supply Cerus Corporation (Nasdaq:CERS) today announced the publication of a study in Transfusion Medicine 1 on the inactivation ...

Cerus Corporation (Nasdaq:CERS) is pleased to announce the recent publication of the 16 th Annual Hemovigilance report by the French National Agency for Medicines and Health Products (ANSM) which oversees the safety of medicine and other health products. The report highlights the safety and ...

Cerus ( CERS -3% ) provides 2020 product revenue guidance range of $89M - $93M representing Y/Y growth of ~20% - 25%. More news on: Cerus Corporation, Healthcare stocks news, , Read more ...

Company provides 2020 product revenue guidance range of $89 million to $93 million representing growth of approximately 20% to 25% over preliminary 2019 full year results Cerus Corporation (Nasdaq:CERS) announced today preliminary product revenue for the fourth quarter and full year 20...